MOD

DESPITE AN ABSENCE OF SYMPTOMS, EoE IS DRIVEN IN PART BY UNDERLYING TYPE 2 INFLAMMATION BENEATH THE SURFACE

IL-4 and IL-13 are drivers of type 2 inflammation, resulting in histologic, endoscopic, and symptomatic manifestations of EoE

IL-4 AND IL-13: KEY DRIVERS OF TYPE 2 INFLAMMATION; IL-13 FUELS FIBROSIS AND MUSCLE HYPERTROPHY^7,8

EoE, eosinophilic esophagitis; TGF-ß, transforming growth factor-beta.

MOA

ONLY DUPIXENT DIRECTLY TARGETS TWO OF THE KEY SOURCES OF EoE: IL-4 AND IL-13 SIGNALING^a

Type 2 inflammation drives local and systemic impacts in patients with EoE

References:

1. Underwood B, Troutman TD, Schwartz JT. Breaking down the complex pathophysiology of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2023;130(1):28-39. doi:10.1016/j.anai.2022.10.026
2. Keegan AD, Leonard WJ, Zhu J. Recent advances in understanding the role of IL-4 signaling. Fac Rev. 2021:10:71. doi:10.12703/r/10-71
3. Chehade M, Falk GW, Aceves S, et al. Examining the role of type 2 inflammation in eosinophilic esophagitis. Gastro Hep Adv. 2022;1(5):720-732. doi:10.1016/j.gastha.2022.05.004
4. Bredenoord AJ, Patel K, Schoepfer AM, et al. Disease burden and unmet need in eosinophilic esophagitis. Am J Gastroenterol. 2022;117(8):1231-1241. doi:10.14309/ajg.0000000000001815
5. Hill DA, Spergel JM. The immunologic mechanisms of eosinophilic esophagitis. Curr Allergy Asthma Rep. 2016;16(2):9. doi:10.1007/s11882-015-0592-3
6. O’Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154(2):333-345. doi:10.1053/j.gastro.2017.06.065
7. Hirano I, Aceves SS. Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis. Gastroenterol Clin North Am. 2014;43(2):297-316. doi:10.1016/j.gtc.2014.02.015
8. Arias A, Lucendo AJ. Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice. Expert Rev Gastroenterol Hepatol. 2019;13(2)99-117. doi:10.1080/17474124.2019.1553617
9. DUPIXENT Summary of Product Characteristics, 2026.